Adjuvant Pembrolizumab Improves DFS, But Not OS, in Locally Advanced/Muscle-Invasive Urothelial Carcinoma
Adjuvant pembrolizumab generated a disease-free survival benefit vs observation in patients with muscle-invasive and locally advanced urothelial carcinoma.
Source: onclive.com